The American Journal of Medicine
Volume 120, Issue 5 , Pages 388-397 , May 2007

Effective Pharmacologic Management of Alzheimer’s Disease

  • Martin R. Farlow, MD

      Affiliations

    • Department of Neurology, Indiana University School of Medicine, Indianapolis
    • Corresponding Author InformationRequests for reprints should be addressed to Martin R. Farlow, MD, Department of Neurology, Indiana University School of Medicine, CL 291, 541 Clinical Drive, Indianapolis, IN 46202-5111.
    • ,
  • Jeffrey L. Cummings, MD

      Affiliations

    • Reed Neurological Research Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif.

References 

  1. Geldmacher DS. Long-term cholinesterase inhibitor therapy for Alzheimer’s disease: practical considerations for the primary care physician. Prim Care Companion J Clin Psychiatry. 2003;5:251–259
  2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders (Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society). JAMA. 1997;278:1363–1371
  3. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry. 1997;154(5 Suppl):1–39
  4. Doody RS, Stevens JC, Beck RN, et al. Practice parameter: management of dementia (an evidence-based review) (Report of the Quality Standards Subcommittee of the American Academy of Neurology). Neurology. 2001;56:1154–1166
  5. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer’s disease: part II (Treatment). Am Fam Physician. 2002;65:2525–2534
  6. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer’s disease: part I (Assessment). Am Fam Physician. 2002;65:2263–2272
  7. Alzheimer’s disease: risk stratification, patient evaluation, and outcome-effective pharmacologic therapy—year 2004 clinical update. Available at: http://www.ahcpub.com. Accessed June 9, 2005.
  8. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427–433
  9. Farlow MR, Anand R, Messina J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol. 2000;44:236–241
  10. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261–2268
  11. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol. 2004;61:252–256
  12. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  13. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137–147
  14. Lemiere J, Van Gool D, Dom R. Treatment of Alzheimer’s disease: an evaluation of the cholinergic approach. Acta Neurol Belg. 1999;99:96–106
  15. Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 2002;9:88–93
  16. Ballard CG. Advances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibition. Eur Neurol. 2002;47:64–70
  17. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int. 2004;45:583–595
  18. Farlow MR. NMDA receptor antagonists (A new therapeutic approach for Alzheimer’s disease). Geriatrics. 2004;59:22–27
  19. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Psychopharmacol. 1998;2:55–65
  20. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ. 1999;318:633–638
  21. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269–2276
  22. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ. 2000;321:1–7
  23. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology. 1998;50:136–145
  24. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease—results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237–244
  25. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481–488
  26. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489–495
  27. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry. 2004;161:532–538
  28. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001;57:613–620
  29. Cummings JL, Anand R, Koumaras B, Hartman R. Behavioral benefits in Alzheimer’s disease patients residing in a nursing home following 52 weeks of rivastigmine treatment. American Psychiatric Association 2000 Annual Meeting: The Doctor-Patient Relationship: New Research Abstracts. 2000;212–213
  30. Marin D, Amaya K, Casciano R, et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer’s disease. Int Psychogeriatr. 2003;15:385–398
  31. Wimo A, Winblad B, Shah SN, Chin W, Zhang R, McRae T. Impact of donepezil treatment for Alzheimer’s disease on caregiver time. Curr Med Res Opin. 2004;20:1221–1225
  32. Lopez OL, Becker S, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2002;72:310–314
  33. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc. 2003;51:937–944
  34. Wimo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord. 2003;15:44–54
  35. Auriacombe S, Pere J-J, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18:129–138
  36. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–1341
  37. Forest Laboratories. Namenda [package insert]. St. Louis, MO, 2003.
  38. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006;63:49–54
  39. Tariot P, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590–1599
  40. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc. 2003;51:737–744
  41. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19:243–249
  42. Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005;3:137–148
  43. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–324
  44. Eisai Inc. Aricept [package insert]. Teaneck, NJ, 2000.
  45. Novartis Pharmaceuticals Corp. Exelon [package insert]. East Hanover, NJ, 2001.
  46. Ortho-McNeil Neurologics Inc. Razadyne [package insert]. Titusville, NJ, 2005.
  47. Ortho-McNeil Neurologics Inc. Razadyne ER [package insert]. Titusville, NJ, 2005.
  48. Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs Aging. 2003;20:437–444
  49. Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry. 2000;15:242–247
  50. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ. 2005;331:321–327
  51. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388
  52. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63:651–657
  53. Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;CD001747
  54. Press release: NICE consults on revised first draft guidance on the use of drugs to treat Alzheimer’s disease (including a review of existing guidance no. 19). Available at: http://www.nice.org.uk/page.aspx?o=289014. Accessed June 8, 2006.
  55. Diamond B, Johnson S, Torsney K, et al. Complementary and alternative medicines in the treatment of dementia: an evidence-based review. Drugs Aging. 2003;20:981–998
  56. Sierpina VS, Sierpina M, Loera JA, Grumbles L. Complementary and integrative approaches to dementia. South Med J. 2005;98:636–645
  57. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002;CD003120
  58. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res. 2005;2:541–551
  59. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;CD000269
  60. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease (The Alzheimer’s Disease Cooperative Study). N Engl J Med. 1997;336:1216–1222
  61. Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer’s disease. Ann Pharmacother. 2005;39:2073–2080
  62. Henderson VW. Estrogen-containing hormone therapy and Alzheimer’s disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience. 2006;138:1031–1039
  63. Almeida OP, Flicker L. Association between hormone replacement therapy and dementia: is it time to forget?. Int Psychogeriatr. 2005;17:155–164
  64. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62:66–71
  65. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30:1204–1215
  66. Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev. 2003;CD001015
  67. Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev. 2003;CD003158
  68. Jansen SL, Forbes DA, Duncan V, Morgan DG. Melatonin for cognitive impairment. Cochrane Database Syst Rev. 2006;CD003802
  69. Malouf R, Areosa Sastre A. Vitamin B12 for cognition. Cochrane Database Syst Rev. 2003;CD004326
  70. Malouf R, Grimley Evans J. The effect of vitamin B6 on cognition. Cochrane Database Syst Rev. 2003;CD004393
  71. Areosa SA, McShane R, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev. 2004;CD003154
  72. Folstein MF, Folstein SE, McHugh PR. ″Mini-mental state (A practical method for grading the cognitive state of patients for the clinician). J Psychiatric Res. 1975;12:189–198
  73. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–186
  74. Morris JC, Edland S, Clark C, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer’s disease. Neurology. 1993;43:2457–2465
  75. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’s disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S22–S32
  76. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323–329
  77. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233–239
  78. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19:707–714

PII: S0002-9343(07)00166-0

doi: 10.1016/j.amjmed.2006.08.036

The American Journal of Medicine
Volume 120, Issue 5 , Pages 388-397 , May 2007

Article Tools

* Image Usage & Resolution